Pomalidomide

Blood

Volumn 122, Issue 14, 2013, Pages 2305-2309

  Lacy, Martha Q ^a   McCurdy, Arleigh R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; POMALIDOMIDE; PREDNISONE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ANEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE MYELOMA; MYELOFIBROSIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL (TOPIC); IMMUNOMODULATION;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84887723566     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-484782     Document Type: Review

References (44)

1. Dimopoulos M, Spencer A, Attal M, et al Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-2132.
2. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17(4):775-779.
3. Rajkumar SV, Jacobus S, Callander NS, et al Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
4. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
5. Weber DM, Chen C, Niesvizky R, et al Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-2142.
6. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
7. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK. 2012;26(1):149-157.
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082-4085.
9. Kumar S, Greipp PR, Haug JL, Gertz MA, Blood E, Rajkumar SV. Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. J Clin Oncol (Meeting Abstracts). 2006;24(18-suppl):7621.
10. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99(11):4079-4086.
11. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-386.
12. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD81 subset. J Exp Med. 1998;187(11):1885-1892.
13. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
14. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killercell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36-45.
15. Ferguson GD, Jensen-Pergakes K, Wilkey C, et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007;27(2):210-220.
16. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683-687.
17. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18):7347-7356.
18. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107(8):3098-3105.
19. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345-1350.
20. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771-4779.
21. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326-2335.
22. Schuster SR, Kortuem KM, Zhu YX, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. ASH Annual Meeting Abstracts. 2012;120(21):194.
23. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276.
24. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51.
25. Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11):1961-1967.
26. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
27. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934-1939.
28. Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. ASH Annual Meeting Abstracts. 2012;120(21):201.
29. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-2975.
30. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: IFM 2009-02. Blood. 2013;121(11)1968-1975.
31. Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide (LEN) and bortezomib (BORT): updated phase 2 results and age subgroup analysis. ASH Annual Meeting Abstracts. 2012;120(21):450.
32. Mark TM, Boyer A, Rossi AC, et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts. 2012;120(21):77.
33. Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study. ASH Annual Meeting Abstracts. 2012;120(21):LBA-6.
34. San-Miguel JF, Weisel KC, Moreau P, et al. MM-003: A phase III, multicenter, randomized, openlabel study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). ASCO Meeting Abstracts. 2013;31(15-suppl):8510.
35. Goldschmidt H, Dimopoulos MA, Weisel KC, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003. ASCO Meeting Abstracts. 2013;31(15-suppl):8528.
36. Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). ASCO Meeting Abstracts. 2013;31(15-suppl):8527.
37. Richardson PGG, Hofmeister CC, Siegel DSD, et al. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). ASCO Meeting Abstracts. 2013;31(15-suppl):8584.
38. Shah JJ, Stadtmauer EA, Abonour R, et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts. 2012;120(21):74.
39. Berenson JR, Hilger JD, Klein LM, et al. A phase 1/2 study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts. 2012;120(21):2979.
40. Palumbo A, Larocca A, Montefusco V, et al. Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts. 2012;120(21):446.
41. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301-304.
42. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol. 2010;85(2):129-130.
43. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563-4569.
44. Geyer HL, Viggiano RW, Lacy MQ, et al. Acute lung toxicity related to pomalidomide. Chest. 2011;140(2):529-533.